Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T12:55:39.617Z.
Calculation as of: 2026-10-06T12:55:39.617Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Attovia Therapeutics, Inc.
Market Cap
$774.32M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$775.72M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$767.46M
Price/OCF Ratio
N/A
TTM Avg
1184.35
3Y Avg
1178.25
5Y Avg
1178.25
Market Cap
$786.48M
Price/OCF Ratio
N/A
TTM Avg
24.89
3Y Avg
136.95
5Y Avg
245.47
Market Cap
$749.55M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$734.10M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $774.32M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $776.24M | N/A | 59.38 | 59.38 | 59.38 |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 1.34 | 2.23 | 2.49 | 4.68 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | N/A | 1184.35 | 1178.25 | 1178.25 |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | N/A | 24.89 | 136.95 | 245.47 |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $812.20M | 9.17 | 9.81 | 9.87 | 15.02 |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | N/A | 422.02 | 258.29 | 228.94 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
